Our discovery that LPAR1 is overexpressed in HCC and the fact that GPCRs are highly druggable targets covering more than 40% of all drugs on the market [27] suggest that targeting LPAR1 is a promising, senescence-inducing therapeutic strategy to combat HCC growth. The gene discussed is LPAR1; the disease is hepatocellular carcinoma.